Content area

Abstract

This protocol demonstrates how to establish primary epithelial cell cultures in vitro from healthy human tissue and human cancer samples using ROCK inhibitor and irradiated feeder cells.

Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue. However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of translational research, including drug discovery and drug target identification. This protocol describes conditional reprogramming (CR), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the presence of a Rho kinase inhibitor (Y-27632). CR cells can be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft studies. The method requires a pathologist to differentiate healthy tissue from tumor tissue, and basic tissue culture skills. The protocol can be used with cells derived from both fresh and cryopreserved tissue samples. As approximately 1 million cells can be generated in 7 d, the technique is directly applicable to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the capacity to become fully differentiated when placed into conditions that mimic their natural environment.

Details

Title
Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens
Author
Liu, Xuefeng 1   VIAFID ORCID Logo  ; Krawczyk Ewa 1 ; Suprynowicz Frank A 1 ; Palechor-Ceron Nancy 1 ; Yuan Hang 1 ; Dakic Aleksandra 1 ; Simic, Vera 1 ; Yun-Ling, Zheng 2 ; Praathibha, Sripadhan 1 ; Chen, Chen 1 ; Lu, Jie 1 ; Tung-Wei, Hou 1 ; Choudhury Sujata 1 ; Kallakury Bhaskar 1 ; Tang, Dean G 3 ; Darling, Thomas 4 ; Thangapazham Rajesh 4 ; Timofeeva Olga 5 ; Dritschilo Anatoly 6 ; Randell, Scott H 7 ; Albanese, Christopher 8 ; Agarwal Seema 1 ; Schlegel, Richard 1 

 Georgetown University Medical Center, Department of Pathology, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Center for Cell Reprogramming, Georgetown University Medical Center, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438) 
 Georgetown University Medical Center, Department of Oncology, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438) 
 University of Texas MD Anderson Cancer Center, Department of Epigenetics and Molecular Carcinogenesis, Smithville, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 Uniformed Services University of the Health Sciences, Department of Dermatology, Bethesda, USA (GRID:grid.265436.0) (ISNI:0000 0001 0421 5525) 
 Georgetown University Medical Center, Department of Oncology, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Georgetown University Medical Center, Department of Radiation Medicine, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438) 
 Georgetown University Medical Center, Department of Radiation Medicine, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438) 
 The University of North Carolina School of Medicine, Department of Cell Biology and Physiology, Chapel Hill, USA (GRID:grid.10698.36) (ISNI:0000000122483208) 
 Georgetown University Medical Center, Department of Pathology, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Center for Cell Reprogramming, Georgetown University Medical Center, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438); Georgetown University Medical Center, Department of Oncology, Washington, USA (GRID:grid.411667.3) (ISNI:0000 0001 2186 0438) 
Pages
439-451
Publication year
2017
Publication date
Feb 2017
Publisher
Nature Publishing Group
ISSN
17542189
e-ISSN
17502799
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2564692988
Copyright
© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2017.